First Name: Ann Last Name: Mertens Institution: Emory University Address 1: 2015 Uppergate Dr Address 2: City: Atlanta State/Province: GA Country: Zip: 30322 Phone: 404-785-0691 Alternate Phone: Email: <u>amerten@emory.edu</u>

Requirements to submit AOI:

A comprehensive review of previously published data has been completed.: Yes The specific aims are clear and focused.: Yes

The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator.: Yes

The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months.: Yes

Project Title: Examining the Role of Transitional Care in Facilitating Quality Clinical Health Care and Preventive Services for Adults Survivors of Childhood Cancer Planned research population (eligibility criteria): Research participants will be eligible to participate in the study if they are adult survivors of childhood and adolescent cancers (initially diagnosed < 19 years) living in the US, currently between the ages of 18 and 50 years of age. Proposed specific aims: In order to affect systems changes within healthcare practice to include systematic and integrated delivery of transitional care services based on the best available evidence, we propose a project with the following objectives: • Objective 1: Examine the type, frequency and integration of evidence-based transitional care services offered to adult survivors with a history of childhood cancer. • Objective 2: Examine the association between health care engagement and physical and psychosocial health outcomes of adult childhood cancer survivors based on their receipt of transitional care services provided to them in their treating institution. Objective 3: Identify which models/ guidelines of TC equate to the highest rate of successful transfer to adult-focused LFTU care. • Objective 4: Examine how survivors' unique personal characteristics (medical, psychosocial and socioeconomic), attitudes about transitional care ( level of thought, interest, anticipated difficulty, and perceived importance of transitional care), and knowledge of individual transitional care serve as facilitators or barriers to successful transition to adult health care providers and receipt of recommended follow-up care. Will the project require non-CCSS funding to complete?: Yes

If yes, what would be the anticipated source(s) and timeline(s) for securing funding?: Funding from the Centers for Disease Control and Prevention (CDC) is anticipated beginning in August

or September of 2013 as part of a sole source contract between CDC and St. Jude Children's Research Hospital.

Does this project require contact of CCSS study subjects for . . .

Additional self-reported information: Yes **Biological Samples: No** Medical record data: No If yes to any of the above, please briefly describe.: Participants meeting eligibility criteria and consent to study participation will be surveyed to assess the following: • Medical, psychosocial and socioeconomic characteristics which impact receipt of preventive and follow-up health care services; • Level of thought, interest, anticipated difficulty, and perceived importance of transition care; • Knowledge of individual transition plans; • Perceived relationship with provider(s); • Retrospective and prospective report of their patient-provider discussions about transition care; • Receipt of care plans and information included in care planning; • The frequency of cancer specific follow-up care and type of providers seen since initial diagnosis; • Type of facility where they receive follow-up care; • Reported secondary malignancies and/or chronic conditions; • If they are receiving general or survivorship focused follow-up care routinely • Report receipt of cancer screening (routine or otherwise) Data collected from selfreported surveys will be used to describe transitional care services for adult survivors of childhood/adolescent cancer and examine the associations between receipt of transitional care and adherence to recommended LTFU within this population.

What CCSS Working Group(s) would likely be involved? (Check all that apply)

Second Malignancy: Chronic Disease: Psychology / Neuropsychology: Genetics: Cancer Control: Primary Epidemiology / Biostatistics:

To describe the anticipated scope of the study, please indicate the specific CCSS data to be included as <u>outcome</u> (primary or secondary) or <u>correlative factors</u>. (Check all that apply)

Late mortality: Second Malignancy: Primary

## Health Behaviors

Tobacco: Secondary Alcohol: Secondary Physical activity: Correlative Factors Medical screening: Primary Other: If other, please specify:

## Psychosocial

Insurance: Secondary Marriage: Correlative Factors Education: Correlative Factors Employment: Correlative Factors Other: If other, please specify:

## Medical conditions

Hearing/Vision/Speech: Hormonal systems: Heart and vascular: Respiratory: Digestive: Surgical procedures: Brain and nervous system: Other: If other, please specify:

Medications

Describe medications:

Pregnancy and offspring: Secondary Family History: Correlative Factors

Psychologic/Quality of Life

BSI-18: Secondary SF-36: Secondary CCSS-NCQ: Secondary PTS: Secondary PTG: Secondary Other: If other, please specify:

Chronic conditions (CTCAE v3): Primary Health status: Primary Demographic

Age: Correlative Factors Race: Correlative Factors Sex: Correlative Factors Others: If others, please specify:

Cancer treatment

Chemotherapy: Correlative Factors Radiation therapy: Correlative Factors Surgery: Correlative Factors

Anticipated sources of statistical support

CCSS Statistical Center: Yes Local institutional statistician: Yes If local, please provide the name(s) and contact information of the statistician(s) to be involved.: Natasha Buchanan, PhD <u>nbuchanan@cdc.gov</u> 770-488-3031 Will this project utilize CCSS biologic samples?: No

If yes, which of the following?

Buccal cell DNA: Peripheral blood: Lymphoblastoid cell lines: Second malignancy pathology samples: Other requiring collection of samples: If other, please explain:

Other general comments: